On 30 March 2023 the proposal for merging Novozymes A/S and Chr. Hansen A/S was approved at general meetings held in the two companies. Novozymes A/S is the continuing company.
Hence, the following changes will be implemented at the exchange:
- Admittance to trading and official listing of 187,298,646 new B shares due to the merger with Chr. Hansen A/S (first day of trading is 31 January 2024).
- Delisting of Chr. Hansen A/S (last day of trading is 30 January 2024).
Novozymes A/S (continuing company) as per 31 January 2024
| ISIN: | DK0060336014 |
| Name: | Novozymes B |
| Volume before change: | 227,256,400 shares (DKK 454,512,800) |
| Change: | 187,298,646 shares (DKK 374,597,292) |
| Volume after change: | 414,555,046 shares (DKK 829,110,092) |
| Face value: | DKK 2 |
| Short name: | NZYM B |
| Unchanged orderbook ID: | 11273 |
Chr. Hansen A/S (discontinuing company)
As a consequence of the merger between Novozymes A/S and Chr. Hansen A/S, Chr. Hansen A/S will be removed from trading and official listing on Nasdaq Copenhagen. Last day of trading shares in Chr. Hansen A/S is 30 January 2024.
| ISIN: | DK0060227585 |
| Name: | Chr. Hansen Holding |
| Listed capital (of DKK 10): | 131,852,496 shares (DKK 1,318,524,960) |
| Last day of trading: | 30 January 2024 |
| CVR NR.: | 12516479 |
| ICB: | 2010 - Health Care |
| Short name: | CHR |
| Orderbook ID: | 75663 |
For further information, please contact: Surveillance, tel. +45 33 93 33 66